VectivBio Holding AG - ESG Rating & Company Profile powered by AI
The ESG rating covers seventeen UN Sustainable Development Goals including: 'Clean Water & Sanitation', 'Climate Action' and 'Life below Water'. This analysis of VectivBio Holding AG uses data from across the web and also from available filings by VectivBio Holding AG. Other corporations in the scoring industry group for VectivBio Holding AG are displayed.
VectivBio Holding AG in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.9; made up of an environmental score of 2.7, social score of 0.0 and governance score of 0.0.
0.9
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1810 | XBiotech Inc | 1.1 | Low |
| 1826 | Mitsubishi Tanabe Pharma Corp | 1.0 | Low |
| 1827 | VectivBio Holding AG | 0.9 | Low |
| 1827 | CannTrust Holdings Inc | 0.9 | Low |
| 1827 | Cannabis Poland SA | 0.9 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does VectivBio Holding AG have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes VectivBio Holding AG disclose current and historical energy intensity?
Sign up for free to unlockDoes VectivBio Holding AG report the average age of the workforce?
Sign up for free to unlockDoes VectivBio Holding AG reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes VectivBio Holding AG disclose its ethnicity pay gap?
Sign up for free to unlockDoes VectivBio Holding AG disclose cybersecurity risks?
Sign up for free to unlockDoes VectivBio Holding AG offer flexible work?
Sign up for free to unlockDoes VectivBio Holding AG have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes VectivBio Holding AG disclose the number of employees in R&D functions?
Sign up for free to unlockDoes VectivBio Holding AG conduct supply chain audits?
Sign up for free to unlockDoes VectivBio Holding AG disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes VectivBio Holding AG conduct 360 degree staff reviews?
Sign up for free to unlockDoes VectivBio Holding AG disclose the individual responsible for D&I?
Sign up for free to unlockDoes VectivBio Holding AG disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes VectivBio Holding AG disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes VectivBio Holding AG disclose water use targets?
Sign up for free to unlockDoes VectivBio Holding AG have careers partnerships with academic institutions?
Sign up for free to unlockDid VectivBio Holding AG have a product recall in the last two years?
Sign up for free to unlockDoes VectivBio Holding AG disclose incidents of discrimination?
Sign up for free to unlockDoes VectivBio Holding AG allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas VectivBio Holding AG issued a profit warning in the past 24 months?
Sign up for free to unlockDoes VectivBio Holding AG disclose parental leave metrics?
Sign up for free to unlockDoes VectivBio Holding AG disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes VectivBio Holding AG disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes VectivBio Holding AG disclose the pay ratio of women to men?
Sign up for free to unlockDoes VectivBio Holding AG support suppliers with sustainability related research and development?
Sign up for free to unlockDoes VectivBio Holding AG disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes VectivBio Holding AG reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs VectivBio Holding AG involved in embryonic stem cell research?
Sign up for free to unlockDoes VectivBio Holding AG disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes VectivBio Holding AG disclose its waste policy?
Sign up for free to unlockDoes VectivBio Holding AG report according to TCFD requirements?
Sign up for free to unlockDoes VectivBio Holding AG disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes VectivBio Holding AG disclose energy use targets?
Sign up for free to unlockDoes VectivBio Holding AG disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes VectivBio Holding AG have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for VectivBio Holding AG
These potential risks are based on the size, segment and geographies of the company.
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.